Cancer and multiple sclerosis in the era of disease-modifying treatments

Multiple sclerosis and cancer in Norway A retrospective cohort study

(2010) R. Midgard et al.   ACTA NEUROLOGICA SCANDINAVICA

CANCER RISK AMONG PATIENTS WITH MULTIPLE SCLEROSIS AND THEIR PARENTS

(2010) S. Hofer et al.   NEUROLOGY

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Natalizumab, multiple sclerosis, and primary central nervous system lymphoma: Enigma, wrapped in mystery, enclosed in conundrum

(2009) Richard M. Ransohoff   ANNALS OF NEUROLOGY

Melanoma following treatment with alemtuzumab for multiple sclerosis

(2009) A. A. Pace et al.   EUROPEAN JOURNAL OF NEUROLOGY

Interferons and multiple sclerosis: is it plausible that β-IFN treatment could influence the risk of cancer among MS patients?

(2009) Elaine Kingwell et al.   Expert Review of Neurotherapeutics

Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence?

(2009) Roberto Bergamaschi et al.   Multiple Sclerosis Journal

Cancer risk among patients with multiple sclerosis and their parents

(2009) S. Bahmanyar et al.   NEUROLOGY

Ensuring the Fiscal Sustainability of Health Care Reform

(2009) Michael E. Chernew et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis

(2008) Christine Lebrun et al.   Multiple Sclerosis Journal

More on Melanoma with Transdifferentiation

(2008)   NEW ENGLAND JOURNAL OF MEDICINE